Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2010 1
2012 1
2013 1
2014 2
2015 2
2016 1
2017 1
2018 4
2019 3
2020 9
2021 5
2022 2
2023 5
2024 4
2025 7
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke.
Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, Yan B, Bush SJ, Dewey HM, Thijs V, Scroop R, Simpson M, Brooks M, Asadi H, Wu TY, Shah DG, Wijeratne T, Ang T, Miteff F, Levi CR, Rodrigues E, Zhao H, Salvaris P, Garcia-Esperon C, Bailey P, Rice H, de Villiers L, Brown H, Redmond K, Leggett D, Fink JN, Collecutt W, Wong AA, Muller C, Coulthard A, Mitchell K, Clouston J, Mahady K, Field D, Ma H, Phan TG, Chong W, Chandra RV, Slater LA, Krause M, Harrington TJ, Faulder KC, Steinfort BS, Bladin CF, Sharma G, Desmond PM, Parsons MW, Donnan GA, Davis SM; EXTEND-IA TNK Investigators. Campbell BCV, et al. N Engl J Med. 2018 Apr 26;378(17):1573-1582. doi: 10.1056/NEJMoa1716405. N Engl J Med. 2018. PMID: 29694815 Free article. Clinical Trial.
Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study.
COVIDSurg Collaborative. COVIDSurg Collaborative. Lancet Oncol. 2021 Nov;22(11):1507-1517. doi: 10.1016/S1470-2045(21)00493-9. Epub 2021 Oct 5. Lancet Oncol. 2021. PMID: 34624250 Free PMC article. Clinical Trial.
Light restrictions were associated with a 0.6% non-operation rate (26 of 4521), moderate lockdowns with a 5.5% rate (201 of 3646; adjusted hazard ratio [HR] 0.81, 95% CI 0.77-0.84; p<0.0001), and full lockdowns with a 15.0% rate (1775 of 11 827; HR 0.51, 0.50-0.5 …
Light restrictions were associated with a 0.6% non-operation rate (26 of 4521), moderate lockdowns with a 5.5% rate (201 of 3646; adjusted h …
Association of childhood and adolescence obesity with incidence and mortality of adulthood cancers. A systematic review and meta-analysis.
Mohammadian Khonsari N, Shahrestanaki E, Ehsani A, Asadi S, Sokoty L, Mohammadpoor Nami S, Hakak-Zargar B, Qorbani M. Mohammadian Khonsari N, et al. Front Endocrinol (Lausanne). 2023 Jan 19;14:1069164. doi: 10.3389/fendo.2023.1069164. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 36742402 Free PMC article.
Based on the random-effects model meta-analysis, childhood obesity increased the hazard of cancer incidence and mortality in adulthood by 33% (HR: 1.33, 95%CI (1.25, 1.41)) and by 28% (HR: 1.28, 95%CI (1.13, 1.42)), respectively. In the subgroups meta-analysis, the …
Based on the random-effects model meta-analysis, childhood obesity increased the hazard of cancer incidence and mortality in adulthood by 33 …
Prediction of persistent incomplete occlusion of intracranial aneurysms treated with woven EndoBridge device.
Essibayi MA, Jabal MS, Jamil H, Salim HA, Musmar B, Adeeb N, Dibas M, Cancelliere NM, Bengzon JD, Algin O, Ghozy S, Lay SV, Guenego A, Renieri L, Carnevale J, Saliou G, Mastorakos P, Naamani KE, Shotar E, Möhlenbruch M, Kral M, Chung C, Salem MM, Lylyk I, Foreman PM, Shaikh H, Župančić V, Hafeez MU, Catapano J, Waqas M, Besler MS, Gunes YC, Rabinov JD, Maingard J, Schirmer CM, Piano M, Kühn AL, Michelozzi C, Starke RM, Hassan A, Ogilvie M, Nguyen A, Jones J, Brinjikji W, Nawka MT, Psychogios M, Ulfert C, Pukenas B, Burkhardt JK, Huynh T, Martinez-Gutierrez JC, Sheth SA, Slawski D, Tawk R, Pulli B, Lubicz B, Panni P, Puri AS, Pero G, Raz E, Griessenauer CJ, Asadi H, Siddiqui A, Levy EI, Khatri D, Haranhalli N, Ducruet AF, Albuquerque FC, Regenhardt RW, Stapleton CJ, Kan P, Kalousek V, Lylyk P, Boddu S, Knopman J, Tjoumakaris SI, Cuellar-Saenz HH, Jabbour PM, Clarençon F, Limbucci N, Pereira VM, Patel AB, Altschul DJ, Dmytriw AA; WorldWideWEB Consortium Collaborators. Essibayi MA, et al. Neurosurg Rev. 2025 Mar 22;48(1):314. doi: 10.1007/s10143-025-03439-8. Neurosurg Rev. 2025. PMID: 40119209 Free PMC article.

On Cox regression. larger aneurysm neck diameter (HR 1.13, 95% CI 1.01-1.27, p = 0.027) and height (HR 1.14, 95% CI 1.02-1.26, p = 0.017), and radial access (HR 2.68, 95% CI 1.76-4.07, p < 0.001) increased, while posterior circulation location (HR 0

…
On Cox regression. larger aneurysm neck diameter (HR 1.13, 95% CI 1.01-1.27, p = 0.027) and height (HR 1.14, 95% CI 1.02-1.26, …
Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. RECOVERY Collaborative Group. Lancet Infect Dis. 2025 Sep;25(9):1000-1010. doi: 10.1016/S1473-3099(25)00093-3. Epub 2025 May 15. Lancet Infect Dis. 2025. PMID: 40383127 Free PMC article. Clinical Trial.
In the molnupiravir comparison, 74 (17%) participants allocated to molnupiravir and 79 (17%) allocated to usual care died within 28 days (hazard ratio [HR] 0.93 [95% CI 0.68-1.28], p=0.66). In the nirmatrelvir-ritonavir comparison, 13 (19%) participants allocated to nirmat …
In the molnupiravir comparison, 74 (17%) participants allocated to molnupiravir and 79 (17%) allocated to usual care died within 28 days (ha …
Waist to height ratio as a simple tool for predicting mortality: a systematic review and meta-analysis.
Abdi Dezfouli R, Mohammadian Khonsari N, Hosseinpour A, Asadi S, Ejtahed HS, Qorbani M. Abdi Dezfouli R, et al. Int J Obes (Lond). 2023 Dec;47(12):1286-1301. doi: 10.1038/s41366-023-01388-0. Epub 2023 Sep 28. Int J Obes (Lond). 2023. PMID: 37770574
Data were extracted from cohort studies reporting effect size (hazard ratio (HR)) regarding the association between WHtR as a continuous (per 1 SD increment) or categorical (highest/lowest) measure and all-cause and cause-specific mortality. ...Random effect meta-analysis …
Data were extracted from cohort studies reporting effect size (hazard ratio (HR)) regarding the association between WHtR as a continu …
Prognostic Significance of Albumin in Modern Left Ventricular Assist Device Therapy: Relevance in the HeartMate 3 Era?
Moayedifar R, Celik M, Karner B, Schaefer AK, Al Asadi H, Marko C, Ruoff L, Zimpfer D, Riebandt J, Schlöglhofer T. Moayedifar R, et al. J Clin Med. 2025 Sep 2;14(17):6193. doi: 10.3390/jcm14176193. J Clin Med. 2025. PMID: 40943953 Free PMC article.

Freedom from HRAEs was significantly lower in the hypoalbuminemia group (45.2% vs. 69.8%, p < 0.001) and competing risk-adjusted cumulative incidence for HRAE was higher, but did not reach statistical significance (p = 0.11), one-year HRAE-free survival was also reduced (68.5%

…

Freedom from HRAEs was significantly lower in the hypoalbuminemia group (45.2% vs. 69.8%, p < 0.001) and competing risk-adjusted cumulati

…
Production of Egg Yolk Antibody (IgY) Against Vibrio Cholerae O1: Protective Effect in Mice.
Shoushtari M, Shooshtari AB, Asadi S, Karami Y, Honari M, Alizadeh GA, Zeinoddini M, Fathi J. Shoushtari M, et al. Avicenna J Med Biotechnol. 2023 Oct-Dec;15(4):239-244. doi: 10.18502/ajmb.v15i4.13497. Avicenna J Med Biotechnol. 2023. PMID: 38078337 Free PMC article.
The anti-V. cholera IgY was administered at 2, 4, 6 hr intervals after 3 hr of inoculation of mice with V. cholerae O1. RESULTS: Results showed that the rate of surviving mice (2 mg/ml of IgY) were 60% after 4 hr and 40% after 6 hr and the rate of surv …
The anti-V. cholera IgY was administered at 2, 4, 6 hr intervals after 3 hr of inoculation of mice with V. cholerae O1. RESULT …
Prevalence and disease trajectories of pulmonary fibrosis of childhood interstitial lung disease: a register-based, multicentre observational study.
Griese M, Reu-Hofer S, Ley-Zaporozhan J, Kammer B, Krüger-Stollfuß I, Micic S, Carlens J, Maier P, Rodler J, Mauss-Schwarzer K, Tran NB, Rapp CK, Gothe F, Marczak H, Lange J, Krenke K, Ring AM, Buchvald F, Stehling F, Jerkic PS, Trischler J, Proesmans M, Sismanlar T, Aslan A, Emiralioğlu N, Kiper N, Hämmerling S, Kılınç A, Prenzel F, Wiemers A, Moreno-Galdo A, Mayell S, Bhatt JM, Naehrlich L, Pahlke F, Wetzke M, Moeller A, Kappler M; chILD-EU collaborators; Schwerk N, Seidl E. Griese M, et al. Lancet Respir Med. 2026 Jun 24:S2213-2600(26)00052-4. doi: 10.1016/S2213-2600(26)00052-4. Online ahead of print. Lancet Respir Med. 2026. PMID: 42341791 Free article.
Survival after enrolment was lower in children who fulfilled fibrosis(register) criteria than in those who did not fulfil fibrosis(register) criteria (log-rank p=0.0029; unadjusted hazard ratio (HR) for death or lung transplantation 1.64 [95% CI 1.18-2.28]). The increased …
Survival after enrolment was lower in children who fulfilled fibrosis(register) criteria than in those who did not fulfil fibrosis(register) …
Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer.
Weickhardt AJ, Williams DS, Lee CK, Chionh F, Simes J, Murone C, Wilson K, Parry MM, Asadi K, Scott AM, Punt CJ, Nagtegaal ID, Price TJ, Mariadason JM, Tebbutt NC. Weickhardt AJ, et al. Br J Cancer. 2015 Jun 30;113(1):37-45. doi: 10.1038/bjc.2015.209. Br J Cancer. 2015. PMID: 26125443 Free PMC article. Clinical Trial.
RESULTS: Patients with low expression of VEGF-D (0, 1th) benefited from bevacizumab treatment (PFS hazard ratio (HR) (C vs CBthCBM), 0.21; 95% CI, 0.08-0.55; overall survival (OS) HR, 0.35; 95% CI, 0.13-0.90). Patients with higher VEGF-D expression received less ben …
RESULTS: Patients with low expression of VEGF-D (0, 1th) benefited from bevacizumab treatment (PFS hazard ratio (HR) (C vs CBthCBM), …
46 results